



FINANCIAL TEAR SHEET

CORPORATE PROFILE

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in refractory indolent Non-Hodgkin's Lymphoma (iNHL) and is currently being evaluated in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.

PRIMARY IR CONTACT

Brian Sullivan
 Corporate Development
Phone: 781-292-4214
Fax: 617-812-0059
E-mail:
bsullivan@verastem.com

STOCK PERFORMANCE

VSTM (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$2.44
Change (%)	▲ 0.09 (3.83%)
Volume	186,456
52 Week Low	\$1.05
Market Cap	\$90,261,500
Rolling EPS	-1.12
PE Ratio	N/A
Shares Outstanding	36,992,418



Data as of 05/22/17 12:09 p.m. ET

RECENT HEADLINES & EVENTS

05/18/17 - 6:44 a.m.

[Verastem Announces Duvelisib Data Presentations at the 22nd Congress of the European Hematology Association](#)

05/10/17 - 4:06 p.m.

[Verastem Reports First Quarter 2017 Financial Results](#)

05/03/17 - 7:00 a.m.

[Verastem Announces Long Term Follow-up Data from the DYNAMO Study Selected for Oral Presentation at the 14th International Conference on Malignant Lymphoma](#)

SEC FILINGS

Filing Date	Form
05/17/17	4
05/10/17	10-Q
05/03/17	3
05/02/17	8-K

Date	Title
06/15/17 3:40 p.m. CET	Verastem Inc at 14th International Conference on Malignant Lymphoma

CORPORATE GOVERNANCE

[Robert Forrester, LL.B.](#) President/Chief Executive Officer

[Jonathan Pachter, Ph.D.](#) Chief Scientific Officer

[Dan Paterson](#) Chief Operating Officer

[Hagop Youssoufian, MSc, M.D.](#) Head of Hematology and Oncology Development

[Steven Bloom](#) Vice President, Corporate Development

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed